Southwest Oncology Group

2020 ◽  
Author(s):  
Keyword(s):  
Oncology Group ◽  
Southwest Oncology Group

273: Timing of Recurrence and Outcomes Following Induction BCG for High Risk TA, T1 Bladder Cancer - A Southwest Oncology Group Trial

2004 ◽  
Vol 171 (4S) ◽  
pp. 72-72
Author(s):  
Seth P. Lerner ◽  
Cathy Tangen ◽  
Heidi Sucharew ◽  
David P. Wood ◽  
E. David Crawford
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Group Trial

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study

1993 ◽  
Vol 15 (1) ◽  
pp. 75-77 ◽  
Author(s):  
J. Wendall Goodwin ◽  
John Crowley ◽  
Harmon J. Eyre ◽  
Benjamin Stafford ◽  
Kurt A. Jaeckle ◽  
...  
Keyword(s):  
Phase Ii ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Southwest Oncology Group ◽  
Southwest Oncology Group Study

Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014

2008 ◽  
Vol 26 (14) ◽  
pp. 2258-2263 ◽  
Author(s):  
Daniel O. Persky ◽  
Joseph M. Unger ◽  
Catherine M. Spier ◽  
Baldassarre Stea ◽  
Michael LeBlanc ◽  
...  
Keyword(s):  
B Cell ◽  
Phase Ii ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
B Cell Lymphoma ◽  
Serum Lactate Dehydrogenase ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Limited Stage ◽  
Involved Field

Purpose To evaluate the effect of rituximab in limited-stage diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter phase II trial combining rituximab with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP) followed by involved-field radiation therapy (IFRT). Patients and Methods Southwest Oncology Group (SWOG) study S0014 enrolled patients with newly diagnosed, aggressive, CD20-expressing non-Hodgkin's lymphoma (NHL). Patients had limited-stage disease and at least one adverse risk factor as defined by the stage-modified International Prognostic Index (nonbulky stage II disease, age > 60 years, WHO performance status of 2, or elevated serum lactate dehydrogenase). Four doses of rituximab were infused on days −7, 1, 22, and 43, and CHOP was administered on days 3, 24, and 45, followed 3 weeks later by 40 to 46 Gy of IFRT. Results Sixty patients with aggressive NHL were eligible. With the median follow-up of 5.3 years, treatment resulted in a progression-free survival (PFS) of 93% at 2 years and 88% at 4 years. Overall survival (OS) was 95% at 2 years and 92% at 4 years. These results were compared with those from a historic group of patients treated without rituximab on S8736, demonstrating PFS of 78% and OS of 88% at 4 years. Conclusion In limited-stage DLBCL, the addition of rituximab to three cycles of CHOP plus IFRT met prespecified study criteria of efficacy, with 2-year PFS of at least 84%, meriting further investigation. There is a pattern of continuing relapse with modest survival gains. We hypothesize that such a pattern may be the result of biologic differences between limited- and advanced-stage lymphoma.

scholarly journals Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420

2010 ◽  
Vol 28 (20) ◽  
pp. 3330-3335 ◽  
Author(s):  
Stephen K. Williamson ◽  
James Moon ◽  
Chao H. Huang ◽  
Perry P. Guaglianone ◽  
Michael LeBlanc ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Single Agent ◽  
Response Probability ◽  
Oncology Group ◽  
Southwest Oncology Group

Purpose We conducted a phase II trial to evaluate the efficacy and safety of single-agent sorafenib in chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). The primary end point was response probability (ie, confirmed complete and partial response [PR]). Patients and Methods Chemotherapy-naïve patients with metastatic, persistent, or recurrent SCCHN who received one induction or fewer or received an adjuvant chemotherapy regimen, who had adequate organ function, and who had a performance status ≤ 1 were eligible. Sorafenib was administered orally at 400 mg twice daily on a continuous basis in 28-day cycles. Responses were evaluated according to RECIST (Response Evaluation Criteria in Solid Tumors). Results Sorafenib was generally well tolerated. Of the 41 eligible patients assessed for adverse events, one experienced a grade 4 adverse event as a result of an asymptomatic pulmonary embolus. The most common grades 2 to 3 adverse events were fatigue, anorexia, stomatitis/oral pain, abdominal pain, hand-foot syndrome, weight loss, and hypertension. There was one confirmed PR and two unconfirmed PRs. The estimated confirmed response probability was 2% (95% CI, 0% to 13%). The estimated median progression-free survival was 4 months (95% CI, 2 to 4 months), and the estimated median overall survival was 9 months (95% CI, 7 to 14 months). Conclusion Sorafenib was well tolerated. Although response was poor, progression-free and overall survival times compare favorably with previous Southwest Oncology Group, phase II, single-agent trials.

Institutional performance in application of the FAB classification of acute leukemia. The southwest oncology group experience

Cancer ◽  
1985 ◽  
Vol 55 (9) ◽  
pp. 1979-1986 ◽  
Author(s):  
David R. Head ◽  
Catherine M. Craven ◽  
Lizardo Cerezo ◽  
Richard A. Savage ◽  
John N. Bickers ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Institutional Performance ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Fab Classification ◽  
Group Experience
Sign in / Sign up

Export Citation Format

Share Document